Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new pharmaceutical form (solution for injection) of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.  Keytruda SC, as it will be marketed in the European Union (EU), [known as Keytruda Qlextm (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.], is a subcutaneous injection containing pembroli...